Frankfurt
06.06.25 | 08:01
0,090 Euro
-2,81 % -0,003
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.05. | Isofol Medical AB: Isofol Medical AB (publ) publishes Interim report, January - March 2025 | 60 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 21, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January - March 2025 is now available on the company's... ► Artikel lesen | |
| 03.04. | Isofol (ST: ISOFOL) to receive financing to support Phase II & III trials of arfolitixorin in Japan | 281 | Edison Investment Research | Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the... ► Artikel lesen | |
| 19.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2024 | 63 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 19, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January - December 2024 is now available on the company's... ► Artikel lesen | |
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2024 | 177 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-September 2024 is now available, in Swedish... ► Artikel lesen | |
| 17.09.24 | Isofol Medical AB: Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin | 376 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 17, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a new international product... ► Artikel lesen | |
| 21.08.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2024 | 235 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 21, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2024 is now available, in Swedish, on the... ► Artikel lesen | |
| 30.07.24 | Isofol Medical AB: Isofol appoints Magdalena Hagman as new Chief Financial Officer | 268 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 30, 2024 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed Margareta Hagman as the new Chief Financial Officer. She has extensive... ► Artikel lesen | |
| 16.07.24 | Isofol Medical AB: Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin | 372 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 16, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces results from two preclinical studies that support the dose-response relationship for arfolitixorin.... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,732 | -0,15 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH 03.06.2025 / 14:27 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,146 | +0,37 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,218 | -1,30 % | H.C. Wainwright initiates Cardiol Therapeutics stock with buy rating | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,000 | +1,26 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
| CENTOGENE | 0,120 | 0,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 2,141 | +1,04 % | Atai Life Sciences: Big Deal | Fast genau vier Jahre nach dem Börsenstart am 18. Juni 2021 gibt es signifikante Veränderungen bei Atai Life Science: So schließt sich das auf die Behandlung psychischer Erkrankungen spezialisierte... ► Artikel lesen | |
| BIOMERIEUX | 121,60 | -0,33 % | BIOMERIEUX: bioMérieux launches cutting-edge equine infectious respiratory disease testing | ||
| CYCLACEL | 0,356 | -41,16 % | Cyclacel Pharmaceuticals, Inc.: Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement | KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company that develops innovative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,875 | -5,41 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| GENUS | 23,000 | -0,86 % | Dividendenbekanntmachungen (04.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERICAN EXPRESS COMPANY US0258161092 0,82 USD 0,742 EUR BARCLAYS PLC GB0031348658 0,055 GBP EUR BRISTOL-MYERS SQUIBB COMPANY US1101221083 0... ► Artikel lesen | |
| ABIONYX PHARMA | 1,220 | +0,16 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX)
Market:... ► Artikel lesen | |
| ANAPTYSBIO | 18,900 | -9,13 % | AnaptysBio, Inc.: Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA | Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month? blinded treatment periodFavorable safety and tolerability, particularly... ► Artikel lesen | |
| MEIRAGTX | 4,700 | +0,43 % | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease | - This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits... ► Artikel lesen |
ISOFOL MEDICAL AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,090 Euro und damit -2,81 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.